DexCom (DXCM) is back in focus after US regulators cleared its Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children who do not use insulin, expanding its reach in the pediatric market.

At a share price of US$72.47, DexCom’s recent 90-day share price return of 8.24% contrasts with a 1-year total shareholder return that declined 9.41%. This suggests recent momentum has picked up after a weaker period, as investors weigh the pediatric Stelo clearance and G7 data alongside longer term performance.

If DexCom’s pediatric CGM approval has you thinking about where health technology could go next, this is a good moment to look at other healthcare AI opportunities using the 40 healthcare AI stocks

With DexCom shares around US$72.47, recent gains sit against a weaker 1-year and 3-year track record. This raises a key question for investors: is this pricing still conservative or already reflecting future growth expectations?

Most Popular Narrative: 13.1% Undervalued

On the latest narrative, DexCom’s fair value of $83.42 sits above the current $72.47 share price, which puts the focus squarely on what assumptions drive that gap.

The rapid adoption of digital health, including remote monitoring, and increased integration of DexCom's CGMs with EHRs (e.g., Epic) and health wearables (like Oura), enhances differentiation, strengthens recurring device and software revenues, and increases patient retention, supporting both revenue growth and higher net margins.

Want to see what sits behind that projected fair value for DexCom? The narrative leans heavily on recurring device uptake, expanding coverage, and a richer profit profile over time.

Result: Fair Value of $83.42 (UNDERVALUED)

However, DexCom’s story could change quickly if Medicare pricing pressure affects CGM reimbursement or if supply chain issues and product recalls weigh on costs and execution.

Another View: DexCom Through Earnings Multiples

The SWS DCF model points to upside for DexCom, yet the P/E picture is less forgiving. At around 30.1x earnings, the stock trades above the US Medical Equipment industry on 24.4x, peers on 20.5x, and even its own 29.8x fair ratio. This means there is less margin for error if expectations soften.

For a closer look at how those earnings ratios compare with what the fair ratio suggests the market could move toward, take a moment to review the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on DexCom split between potential upside and valuation risk, it makes sense to move quickly, review the same data, and decide whether the rewards justify the current pricing with the 3 key rewards

Looking for more investment ideas beyond DexCom?

If DexCom has sharpened your focus on opportunities, do not stop here. Broadening your watchlist now could help you spot the next compelling setup sooner.

• Target potential mispricing by scanning companies that combine quality with valuation support using the 45 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that offer higher yields and steady payouts through the 8 dividend fortresses.
• Prioritise resilience by searching for companies with robust financial footing and low risk profiles via the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.